Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Leases (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Current Leases for 4 consecutive years, with $12.8 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Current Leases fell 1.84% year-over-year to $12.8 million, compared with a TTM value of $12.8 million through Mar 2025, down 1.84%, and an annual FY2024 reading of $1.0 million, up 13.44% over the prior year.
  • Current Leases was $12.8 million for Q1 2025 at Atara Biotherapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $13.1 million in Q1 2024 and bottomed at $834000.0 in Q4 2022.
  • Average Current Leases over 4 years is $7.6 million, with a median of $12.1 million recorded in 2023.
  • The sharpest move saw Current Leases rose 13.44% in 2024, then dropped 1.84% in 2025.
  • Year by year, Current Leases stood at $834000.0 in 2022, then rose by 9.71% to $915000.0 in 2023, then grew by 13.44% to $1.0 million in 2024, then surged by 1137.57% to $12.8 million in 2025.
  • Business Quant data shows Current Leases for ATRA at $12.8 million in Q1 2025, $1.0 million in Q4 2024, and $13.1 million in Q1 2024.